What’s in Applied Genetic Technologies Corporation (AGTC) After Today’s Big Increase?

April 17, 2018 - By Larry Anderson

Applied Genetic Technologies Corporation (NASDAQ:AGTC) Logo

Investors sentiment decreased to 0.55 in 2017 Q4. Its down 0.02, from 0.57 in 2017Q3. It turned negative, as 10 investors sold Applied Genetic Technologies Corporation shares while 21 reduced holdings. 10 funds opened positions while 7 raised stakes. 6.64 million shares or 2.25% less from 6.79 million shares in 2017Q3 were reported.
Qs Ltd invested in 300 shares or 0% of the stock. Gsa Capital Ptnrs Llp reported 66,900 shares stake. Renaissance Tech Limited Company owns 444,428 shares for 0% of their portfolio. Jacobs Levy Equity holds 0% of its portfolio in Applied Genetic Technologies Corporation (NASDAQ:AGTC) for 14,000 shares. Clarivest Asset Mgmt invested in 0.01% or 122,353 shares. Price T Rowe Associate Md stated it has 0% of its portfolio in Applied Genetic Technologies Corporation (NASDAQ:AGTC). Moreover, Barclays Plc has 0% invested in Applied Genetic Technologies Corporation (NASDAQ:AGTC) for 84 shares. Vanguard Gp Inc holds 0% of its portfolio in Applied Genetic Technologies Corporation (NASDAQ:AGTC) for 452,675 shares. Mufg Americas owns 225 shares or 0% of their US portfolio. Royal State Bank Of Canada owns 1,964 shares or 0% of their US portfolio. Altrinsic Global Advisors Lc has invested 0.03% of its portfolio in Applied Genetic Technologies Corporation (NASDAQ:AGTC). Tudor Corp Et Al holds 14,839 shares or 0% of its portfolio. Connor Clark & Lunn Invest Mngmt Ltd has 0% invested in Applied Genetic Technologies Corporation (NASDAQ:AGTC) for 60,675 shares. D E Shaw & Com reported 0% in Applied Genetic Technologies Corporation (NASDAQ:AGTC). Federated Pa, Pennsylvania-based fund reported 1,080 shares.

The stock of Applied Genetic Technologies Corporation (NASDAQ:AGTC) is a huge mover today! The stock increased 10.20% or $0.5 during the last trading session, reaching $5.4. About 196,730 shares traded or 85.07% up from the average. Applied Genetic Technologies Corporation (NASDAQ:AGTC) has declined 39.42% since April 17, 2017 and is downtrending. It has underperformed by 50.97% the S&P500.
The move comes after 8 months positive chart setup for the $97.77 million company. It was reported on Apr, 17 by Barchart.com. We have $5.67 PT which if reached, will make NASDAQ:AGTC worth $4.89 million more.

Analysts await Applied Genetic Technologies Corporation (NASDAQ:AGTC) to report earnings on May, 9. They expect $-0.25 earnings per share, down 400.00 % or $0.20 from last year’s $-0.05 per share. After $-0.29 actual earnings per share reported by Applied Genetic Technologies Corporation for the previous quarter, Wall Street now forecasts -13.79 % EPS growth.

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. The company has market cap of $97.77 million. The company's lead products consist of four ophthalmology development programs across three targets, including X-linked retinoschisis that is in Phase I/II clinical trials; X-linked retinitis pigmentosa, which is in Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials for the treatment of inherited retinal diseases, as well as a preclinical program in adrenoleukodystrophy, which is a disease of the central nervous system and otology. It currently has negative earnings. It has collaboration agreements with Biogen MA, Inc., 4D Molecular Therapeutics, Synpromics Limited, and Bionic Sight, LLC, as well as the University of Florida Research Foundation.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.